Hyperfractionated radiotherapy for T2N0 glottic carcinoma: A retrospective analysis at 10 years follow-up in a series of 60 consecutive patients

Mario Bignardi, Paolo Antognoni, Giuseppe Sanguineti, Alessandro Magli, Marinella Molteni, Anna Merlotti, Antonella Richetti, Michele Tordiglione, Leopolde Conte, Lorenzo Magno

Research output: Contribution to journalArticlepeer-review


Aims and background: To report results of hyperfractionated radiotherapy for T2N0 glottic carcinoma at a single institution after extended follow-up. Methods: Between 1980 and 1988 at Varese University Hospital, 60 consecutive patients with T2N0 glottic carcinoma received exclusive radiotherapy consisting of 1.5 Gy/fraction twice a day. Treatment gaps during the radiotherapy course were allowed according to individual tolerance. This policy resulted in a wide range of elapsed treatment time: median, 5.7 weeks; range, 3.7-8.9. Median follow-up is 9.8 years. Results: As a result of dose/time distribution, 16, 20 and 24 patients received an average weekly dose rate of 10 Gy/week, respectively. Mean total dose for each group was 62.8 Gy, 63.7 Gy and 63.8 Gy, respectively. Five-year local-regional control was 69 ± 6% (95% CI); ultimate local-regional control, including salvage surgery, was 78 ± 5%. All failures were at the primary site, and no patient developed neck recurrence as first site of failure. The actuarial incidence of grade 2-3 late reactions at 5 years was 42 ± 6%. Most late toxicity events were grade 2: only 2 patients developed grade 3 reactions and none grade 4. None of the several clinical and treatment-related variables showed any statistically significant impact on local-regional control or late toxicity at univariate and multivariate analysis. In particular, 3-year local-regional control rates were 73 ± 11%, 84 ± 8% and 69 ± 10% for an average weekly dose rate of 10 Gy/week, respectively (not significantly different). Conclusions: At a very long follow-up, the hyperfractionated regimen tested in the study was shown to be effective and devoid of major complications, provided individual patient acute tolerance is carefully taken into account. Also, time factor did not affect outcome in this series.

Original languageEnglish
Pages (from-to)317-323
Number of pages7
Issue number3
Publication statusPublished - May 2004


  • Glottic cancer
  • Hyperfractionation
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'Hyperfractionated radiotherapy for T2N0 glottic carcinoma: A retrospective analysis at 10 years follow-up in a series of 60 consecutive patients'. Together they form a unique fingerprint.

Cite this